Project description:Investigation of whole genome gene expression level changes in human osteosarcoma cell line MNNG/HOS treated by TGF-beta1 for three days (mesophase) and five days (sarcospheres iOSCs), compared to non-treatment cells (residual adherent cells). A three chip study using total RNA cover from three cultures of non-treatment human osteosarcoma cell line MNNG/HOS (residual adherent cells), TGF-beta1 treated three days osteosarcoma cell line MNNG/HOS (mesophase) and TGF-beta1 treated five days osteosarcoma cell line MNNG/HOS ( only collected the suspending sarcospheres iOSCs). Each chip measures the expression level of 45033 genes from osteosarcoma cell line MNNG/HOS.
Project description:We report the expression differences between 5DAG Arabidopsis Col-0, rpn10-1, and rpn12a-1 seedlings treated with 100 uM MG132 for 0, 3, or 24 hours.
Project description:This study provides an evaluation of changes in gene expression associated with methapyrilene treatment of rat hepatocytes in vitro. Primary rat hepatocytes were treated for 24 and 48 hours with two doses (3 uM and 100 uM) of methaphyriline and 1% DMSO vehicle control. Five replicates of each treatment were performed. Cells were then extracted and RNA processed for microarray analysis.
Project description:DGKZ could promote proliferation and inhibit apoptosis in osteosarcoma,both in vivo and in vitro. To identify downstream molecular mechanism of DGKZ in proliferation of osteosarcoma, we performed a microarray profiling (Affymetrix) in human HOS cells treated with DGKZ knockdown.
Project description:Whole genome expression data on transcriptome of human osteosarcoma (HOS) cells induced by bisfenol A (BPA), S (BPAS) and AF (BPAF) after short- (8 hours) and long-term (3 months) exposure at human-relevant (10 nM) concentrations.
Project description:Whole genome expression data on transcriptome of human osteosarcoma (HOS) cells induced by bisfenol A (BPA), S (BPAS) and AF (BPAF) after short- (8 hours) and long-term (3 months) exposure at human-relevant (10 nM) concentrations. 8 experimental conditions, 4x2 design: 3 compounds (bisphenol A, S and AF) and a control, 2 exposure times (8 hours and 3 months). 3 replicates for each condition, 24 arrays in total.
Project description:Invastigation of whole genome gene expression level changes in human osteosarcoma cell line MNNG/HOS sarcospheres,hypoxia-induced sarcospheres and TGF-beta1 induced sarcospheres. A three chip study using total RNA cover from three cultures of human osteosarcoma cell line MNNG/HOS sarcospheres, hypoxia-induced sarcospheres and TGF-beta1-induced sarcospheres. Each chip measures the expression level of 45033 genes from osteosarcoma cell line MNNG/HOS.
Project description:We treated for 24 hours the BRAF-V600E melanoma cell line A375 with 7 doses of the RAF inhibitor Vemurafenib and, in a second experimental desing, we treated for 24 hours the BRAF-V600E melanoma cell line A375 with Vemurafenib (1 uM) alone or in combination with the MEK inhibitor Cobimetinib (1 uM) and subsequently stimulated with EGF in a time-course of 7 time points for up to 8 hours (0, 0.5, 1, 2, 3, 4, 8 hours).
Project description:This study provides an evaluation of changes in gene expression associated with beta-naphthaflavone treatment of rat hepatocytes in vitro. Primary rat hepatocytes were treated for 24 and 48 hours with two doses 1 uM and 100 mM) of beta-naphthaflavone and 1% DMSO vehicle control. Five replicates of each treatment were performed. Cells were then extracted and RNA processed for microarray analysis.
Project description:To determine the differentially expreesed genes in osteosarcoma cell lines MG63 and U2OS stimulated with hedgehog ligand (SHH) for 24 hours MG63 and U2OS cells were treated with PBS or 1ug/ml of recombinat human sonic hedgehog for 24 hours. RNA was isolated from the cells and RNAseq performed The results present differentially expressed genes when osteosarcoma cell lines are stimulated with SHH
